AstraZeneca completes acquisition of Icosavax
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination
Launches collaborative centre for translational research in head and neck cancer
The bioprocess business will continue to pioneer contributions to safety and productivity in the manufacture of biotherapeutics
Darunavir is a protease inhibitor antiviral medicine that prevents Human Immunodeficiency Virus (HIV-1) from multiplying in the body
A new GSK survey shows a large number of adults do not understand how shingles may be triggered
Almost 300 million people globally have chronic hepatitis B
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by respiratory syncytial virus
Subscribe To Our Newsletter & Stay Updated